PPAR Agonist

GW 2433 is a dual PPARα and PPARδ agonist. GW 2433 has the potential for the study of type II diabetes and dyslipidemia.

Bezafibrate (Standard) is the analytical standard of Bezafibrate. This product is intended for research and analytical applications. Bezafibrate is an agonist of PPAR, with EC₅₀s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.

Cinoxate-d₃ is deuterium labeled Cinoxate. Cinoxate is a hypertrophic peroxisome proliferator activating receptor γ (PPARγ) agonist with K_i value of 18.0 μM. Cinoxate can be used to study obesity.

ZINC17167211 is a potent PPAR-α agonist (EC₅₀=0.16 nM) that can be used in the study of diabetes, hyperlipidemia, and inflammatory diseases.

Rivoglitazone (Standard) is the analytical standard of Rivoglitazone (HY-106181). This product is intended for research and analytical applications. Rivoglitazone is a thiazolidinedione-derivative PPARγ agonist for the research of type 2 diabetes mellitus.

4-oxo Docosahexaenoic acid (4-oxo DHA) is a putative metabolite of Docosahexaenoic acid (HY-B2167) with antiproliferative and PPARγ agonist activity. It inhibits the growth of several triple negative breast cancer cell lines (MCF-10F, trMCF, bsMCF, MDA-MB-231, and BT549) at 50-100 μM, however it increased proliferation of MCF-7 cells. 4-oxo DHA binds covalently to PPARγ and activates gene transcription in luciferase reporter assays and in dendritic cells with EC₅₀ values of approximately 8-16 μM.

TZD18 is a potent and orally active PPARα and PPARγ dual agonist with IC₅₀ values of 0.028, 0.057, >10 µM for PPARα, PPARγ, PPARδ, respectively. TZD18 reduces plasma levels of both glucose and triglycerides in diabetic mice. TZD18 has the potential for the research of type 2 diabetes.

AVE-8134 is a potent PPARα agonist, with EC₅₀ values of 100 and 3000 nM for human and rodent PPARα receptor, respectively.

GW0742 (Standard) is the analytical standard of GW0742. This product is intended for research and analytical applications. GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.

ZINC08438472 is a potent and selective peroxisome proliferator activated receptors-α (PPAR-α) agonist with an EC₅₀ value of 12.1 nM. ZINC08438472 is promising for research of diabetes, hyperlipidaemia and inflammatory disorders.

Retinoic acid-d₃-1 is the deuterium labeled Retinoic acid (HY-14649). Retinoic acid is a metabolite of vitamin A that plays important roles in cell growth, differentiation, and organogenesis. Retinoic acid is a natural agonist of RAR nuclear receptors, with IC₅₀s of 14 nM for RARα/β/γ. Retinoic acid bind to PPARβ/δ with Kd of 17 nM. Retinoic acid acts as an inhibitor of transcription factor Nrf2 through activation of retinoic acid receptor alpha.

Pemafibrate (Standard) is the analytical standard of Pemafibrate. This product is intended for research and analytical applications. Pemafibrate is a highly selective PPARα agonist, with an EC₅₀ of 1 nM.

CLX-0921 is an orally active PPARγ agonist with an IC₅₀ of 1.54 μM. CLX-0921 has a potent antihyperglycemic activity, and can be used for the study of type 2 diabetes.

7-Hydroxy-3-(3-methoxyphenyl)-4H-chromen-4-one is a dual agonist of PPARα and PPARγ, with an EC₅₀ of 23.10 μM for human PPARα and an EC₅₀ of 22.29 μM for human PPARγ. 7-Hydroxy-3-(3-methoxyphenyl)-4H-chromen-4-one regulates the expression of lipid metabolism-related genes via PPARα, and modulates the expression of genes associated with glucose homeostasis and adipogenesis via PPARγ. 7-Hydroxy-3-(3-methoxyphenyl)-4H-chromen-4-one can be used in the research of type 2 diabetes and metabolic syndrome.

NS-220 is an orally active PPARα agonist with high subtype selectivity, with EC₅₀ values of 1.9×10^-8 M, 9.6×10^-6 M and >10^-4 M for PPARα, PPAR γ and PPARδ, respectively. NS-220 is used in the research for hyperlipidemia or metabolic disorders in type-2 diabetes.

PPARα/γ/δ agonist 1 (Compound 2) is a potent PPARα/γ/δ agonist, with an IC₅₀ of 70 nM for PPARγ. PPARα/γ/δ agonist 1 can be used for the research of type 2 diabetes.

Chiglitazar (Standard) is the analytical standard of Chiglitazar (HY-106266). This product is intended for research and analytical applications. Chiglitazar (Carfloglitazar) is a PPARα/γ dual agonist, with EC₅₀s of 1.2, 0.08, 1.7 μM for PPARα, PPARγ and PPARδ, respectively.